WO2005083074A1 - 腫瘍抗原ペプチド - Google Patents
腫瘍抗原ペプチド Download PDFInfo
- Publication number
- WO2005083074A1 WO2005083074A1 PCT/JP2005/003399 JP2005003399W WO2005083074A1 WO 2005083074 A1 WO2005083074 A1 WO 2005083074A1 JP 2005003399 W JP2005003399 W JP 2005003399W WO 2005083074 A1 WO2005083074 A1 WO 2005083074A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- hla
- cells
- tumor antigen
- derived
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 274
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 118
- 239000000427 antigen Substances 0.000 title claims abstract description 86
- 108091007433 antigens Proteins 0.000 title claims abstract description 86
- 102000036639 antigens Human genes 0.000 title claims abstract description 86
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 61
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 25
- 229940023041 peptide vaccine Drugs 0.000 claims abstract description 21
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims description 105
- 230000027455 binding Effects 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 17
- 210000004698 lymphocyte Anatomy 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 230000000259 anti-tumor effect Effects 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 229940029030 dendritic cell vaccine Drugs 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 71
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 46
- 201000007270 liver cancer Diseases 0.000 description 35
- 208000014018 liver neoplasm Diseases 0.000 description 35
- 230000001472 cytotoxic effect Effects 0.000 description 34
- 201000011510 cancer Diseases 0.000 description 32
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 31
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 230000005867 T cell response Effects 0.000 description 21
- 238000011282 treatment Methods 0.000 description 20
- 238000011830 transgenic mouse model Methods 0.000 description 19
- 108010074328 Interferon-gamma Proteins 0.000 description 18
- 241000699660 Mus musculus Species 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 230000005847 immunogenicity Effects 0.000 description 16
- 102100037850 Interferon gamma Human genes 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 108010041986 DNA Vaccines Proteins 0.000 description 11
- 229940021995 DNA vaccine Drugs 0.000 description 11
- 239000012979 RPMI medium Substances 0.000 description 11
- 238000011510 Elispot assay Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 241000701022 Cytomegalovirus Species 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 239000011651 chromium Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 102100028162 ATP-binding cassette sub-family C member 3 Human genes 0.000 description 6
- 101000986633 Homo sapiens ATP-binding cassette sub-family C member 3 Proteins 0.000 description 6
- 101001122350 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial Proteins 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 210000003850 cellular structure Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- APHFXDBDLKPMTA-UHFFFAOYSA-N 2-(3-decanoyl-4,5,7-trihydroxynaphthalen-2-yl)acetic acid Chemical compound CCCCCCCCCC(=O)c1c(CC(O)=O)cc2cc(O)cc(O)c2c1O APHFXDBDLKPMTA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100024405 GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Human genes 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 101000981252 Homo sapiens GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 2
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 2
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 description 2
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 2
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 2
- 101000836268 Homo sapiens U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 2
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- 241000237988 Patellidae Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 102000046101 human AFP Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000009149 molecular binding Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 101150062356 5.4 gene Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001131829 Homo sapiens P protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000009557 abdominal ultrasonography Methods 0.000 description 1
- 108010063628 acarboxyprothrombin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000002340 cardiotoxin Substances 0.000 description 1
- 231100000677 cardiotoxin Toxicity 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 108700039855 mouse a Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464481—Alpha-feto protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
Definitions
- the present invention relates to a novel peptide useful as a tumor antigen peptide. More specifically, the present invention relates to a novel tumor antigen peptide restricted to HLA-A24, and a peptide vaccine, a DC vaccine, an antibody, and a cytotoxic T cell using the same.
- Immunotherapy is the fourth treatment for cancer after surgery, chemotherapy, and radiation therapy.
- cancer immunotherapy There are various methods for cancer immunotherapy, such as cytodynamic therapy, antibody therapy, cell therapy, peptide vaccine therapy, and gene therapy, but few of them have reached clinical applications due to safety and efficacy issues.
- Peptide vaccine therapy induces both cell-mediated immunity and humoral immunity by administering a tumor antigen or its epitob portion together with an adjuvant, and its clinical application in many countries due to its simplicity and safety. Is underway. Rosenberg et al. Produced a synthetic peptide with enhanced HLA-A2 binding based on the structure of tumor-associated antigens and administered it to patients with melanoma. have reported (Rosenberg SA et al "immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nature Medicine, (1998), 4 (3):..
- the site has a list of peptide vaccines currently undergoing clinical trials.
- the target is sarcoma, leukemia, melanoma, myeloma, and a variety of other subjects.3 ⁇ 4 £ (Ribas A. et ai., 'Current developments in cancer vaccines and cellular immunotherapy. "J Clin Oncol. (2003), 21 (12): p2415-32.) 0
- MHC tumor antigens via MHC (HLA and ⁇ in humans) molecules
- MHC is a major histocompatibility complex located on the cell surface and is roughly classified into Class I and Class II. Class I molecules are present on almost all cell surfaces, present antigens to CD8-positive T cells and activate them into cytotoxic T cells, and Class II molecules are present on cell surfaces such as macrophages and monocytes. Antigen on CD4 + T cells And activate it to helper T cells. Endogenous tumor cells are eaten by antigen-presenting cells, fragmented (tumor antigen peptide), and then form a complex with MHC Class I molecules and presented to T cells. On the other hand, exogenous tumor antigen peptides bind directly to MHC molecules without undergoing intracellular processing and are presented to T cells. MHC is rich in genetic polymorphisms, and individual differences define individual differences in immune responses.
- tumor antigen peptides have been identified so far, but their immunogenicity is restricted to the MHC type of the patient.
- tumor antigens vary within individuals as well.
- clinical applications require consideration of cross-reactivity with other foreign antigens. Therefore, there is always a need for safe and effective novel tumor antigen peptides, and an object of the present invention is to provide such novel tumor antigen peptides.
- the present inventors have synthesized various peptides based on the binding motif of the MHC Class I A24 (HLA-A24) molecule and the amino acid sequence of a known tumor antigen. By confirming the immunogenicity and safety of these peptides, a novel peptide useful as a tumor antigen peptide was identified.
- the present invention relates to SEQ ID NOs: 4, 14, 15, 18, 19, 23, 24, 25, 27, 28, 29, 30, 34, 37, 38, 39, 40, 41, and 44
- a tumor antigen peptide containing the amino acid sequence described in 1 above is provided.
- the tumor antigen peptide of the present invention can be used as an antitumor peptide vaccine by administering it to an HLA-A24-positive cancer patient together with an appropriate adjuvant.
- antigen-presenting cells which are obtained by culturing HLA-A24-positive antigen-presenting cells with the tumor antigen peptide of the present invention and which present the tumor antigen peptide are also used for immunotherapy of HLA-A24-positive cancer patients. Can be used for law.
- the antigen-presenting cells ⁇ cells are preferable.
- the present invention also provides such antitumor peptide vaccines and antigen presenting cells.
- the present invention also relates to SEQ ID NOs: 4, 14, 15, 18, 19, 23, 24, 25, 27, 28, 29, 30, 34, 37, 38, 39, 40, 41, and 44 Provide a nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence IJ described in 1 above. These nucleic acid molecules can be used as antitumor agents for HLA-A24 positive cancer patients, including DNA vaccines.
- the present invention further provides an antibody capable of specifically binding to the tumor antigen peptide of the present invention.
- the antibody can be used as an antitumor agent, or for screening antitumor agents or detecting and diagnosing cancer.
- the present invention provides a method for culturing tumor tissue-infiltrating lymphocytes or peripheral blood lymphocytes isolated from HLA-A24-positive patients together with the tumor antigen peptide of the present invention and IL-2. And methods for inducing cytotoxic T cells. Cytotoxic T cells obtained by the above method can also be used for CTL therapy of HLA-A24-positive cancer patients, and the present invention also provides an antitumor agent containing such cytotoxic T cells.
- a novel peptide useful as a tumor antigen peptide is provided.
- These peptides can be used for the treatment and diagnosis of HLA-A24-positive cancer patients (particularly liver cancer patients), including peptide vaccines and DC vaccines, and for antitumor drug screening.
- FIG. 1 shows specific motifs for HLA binding and CTL recognition.
- FIG. 2 shows the results of an HLA-A24 molecule binding affinity test of AFP-derived peptides (Table 1: Peptide Nos. 27 to 36).
- Fig. 3 shows the results of IFN- ⁇ ELISPOT assay using PBMCs derived from healthy individuals and derived from AFP-derived peptides.
- FIG. 4 shows the results of IFN- ⁇ ELISPOT assay using AFP-derived peptide-derived PBMC derived from a liver cancer patient.
- FIG. 5 shows the results of CTL assay of Peptide No. 27-30.
- Figure 6 confirms that the cytotoxicity of Peptide Nos. 27 and 30 is HAL-A24-restricted and AFP-specific, and that CTLs induced by these peptides damage liver cancer cells.
- FIG. 5 shows the results of CTL assay on various liver cancer cell lines for confirmation.
- FIG. 7-1 shows the results of CTL assay on various liver cancer cell lines to confirm that Peptide No. 30 is restricted to CD8 and HLA-A24 cytotoxicity.
- FIG. 7-2 shows the results of an examination of the immune response of liver cancer patients before and after liver cancer treatment using Peptide Nos. 27, 29 and 30.
- FIG. 8 shows the results of a T cell response (IFN-y ELISPOT assay) when Peptide Nos. 27 and 30 were administered as peptide vaccines to HLA-A24 transgenic mice.
- Fig. 9 shows the results of T cell responses (IFN-y ELISPOT atsey) to each peptide in HLA-A24 transgenic mice to which AFP DNA vaccine was administered.
- FIG. 10 shows the results of CTL assay using HLA-A24 transgenic mice splenocytes immunized with Peptide No. 30 or AFP DNA vaccine.
- FIG. 11 is a graph showing IFN- ⁇ obtained using PBMCs derived from healthy subjects and having the peptides listed in Tables 2 and 3.
- FIG. 12 shows IFN-y obtained by using PBMC derived from a liver cancer patient with the peptides listed in Table 3.
- FIG. 13 shows the results of CTL assay of the peptides shown in Table 3.
- CTL XX in the graph indicates CTL induced by stimulation of Peptide No. XX.
- FIG. 14 shows a difference in T cell response (IFN- ⁇ ELISPOT assay) before and after treatment.
- FIG. 15 shows the results of an HLA-A24 molecule binding affinity test of hTERT-derived peptides (Table 2: Peptide Nos. 37-46).
- FIG. 16 shows the results of IFN-y ELISPOT assays using hTERT-derived peptides using PBMCs derived from healthy individuals and liver cancer patients.
- FIG. 17 shows the results of CTL assay using hTERT-derived peptide from patient peripheral blood lymphocytes.
- FIG. 18 shows the results of CTL assay using a hTERT-derived peptide liver cancer cell line.
- Figure 19 shows changes in T cell responses before and after liver cancer treatment using hTERT-derived peptides. The results of the study conducted using ERISPOT Atsushi are shown.
- Fig. 20 shows the results of T cell response (IFN-y ELISPOT assay) to hTERT-derived peptide in HLA-A24 transgenic mice to which hTERT DNA vaccine was administered.
- MHC molecules have a groove for the binding of antigenic peptides, and tumor antigenic peptides have specific structural motifs for binding to this groove (Bjorkman, PJ, et al., Nature, 1987, 329, p506). -512; Bjorkman, PJ, et al "Nature, 1987, 329, p512-518; Falk, K, et al., Nature, 1991, 351, p290-296; Rammensee, HG, et al., Curr Opin Immunol, 1993, 5, p35-44; Rammensee, HG, Curr Opin Immunol 1995, 7, p85- 96;
- Antigen peptides have an anchor site that determines the binding to MHC molecules and an epitope site that is recognized by cytotoxic T cells (CTLs), and thus trigger CTL activation through antigen-presenting cells (Fig. 1 reference).
- CTLs cytotoxic T cells
- the tumor antigen peptide according to the present invention can be designed using a computer program (for example, BIMAS) based on the known MHC binding motif and the amino acid sequence of the tumor-associated antigen.
- BIMAS computer program
- the database MHCPEP http://wehih.wehi.edu.au/mhcpep/
- MHCPEP http://wehih.wehi.edu.au/mhcpep/
- HLA MHC
- Class 1 molecules are rich in polymorphisms and binding motifs differ depending on their types, it is necessary to first specify the type of HLA to be targeted in tumor antigen peptide design.
- HLA-A24 expressed in 60% of Japanese is targeted, and a peptide of about 915 amino acids having this HLA-A24 binding motif is used as a tumor antigen peptide. Design as a candidate.
- the peptide designed by the above method can be easily chemically synthesized by a well-known method such as solid-phase or liquid-phase synthesis by the Fmoc method or the Boc method, and can be obtained at a desired purity by a known method such as HPLC. it can. If necessary, the peptide may be appropriately modified.
- Peptides can also be prepared by genetic engineering by incorporating the DNA encoding them into a suitable vector and expressing them in host cells.
- the usefulness of the synthesized peptide as a tumor antigen peptide is evaluated by immunogenicity screening using various Atsuy systems. The evaluation can be performed in three stages: binding affinity to MHC molecule, T cell activation, and peptide-specific cytotoxicity
- HLA-A24 MHC Class I molecule expressed on the cell surface.
- the binding affinity to cell surface HLA-A24 is determined by expressing the target HLA-A24 molecule, culturing the test peptide in a cell, and binding the peptide to degrade HLA.
- the expression level of HLA-A24 remaining on the cells may be measured.
- the expression level of HLA-A24 on cells should be measured by FACS (registered trademark) using an anti-MHC monoclonal antibody and a secondary antibody (for example, an anti-mouse immunoglobulin antibody labeled with FITC: manufactured by DAKO). Can be.
- the measured HLA-A24 expression level can be evaluated semi-quantitatively by comparing it to the HLA-A24 expression level of cells to which no peptide was added or cells to which control peptides (negative and positive control groups) were added. it can.
- the immunogenicity of the synthetic peptide can be evaluated by the ability of CD8-positive T cells activated by the peptide to produce cytotoxicity (interferon ⁇ ).
- the amount of cytodynamic force secreted by T cells can be measured by a well-known Atsey method such as ELIbA (Enzyme-Linked Immunosorvent Assay) or ELISPOT (Enzyme-Linked Immunospot Assay).
- ELIbA Enzyme-Linked Immunosorvent Assay
- ELISPOT Enzyme-Linked Immunospot Assay
- kits made by MABTECH, etc.
- such a commercially available kit can be suitably used.
- the ELISPOT assay is a highly sensitive method for quantifying cytodynamic secretory cells and antibody-producing cells by the immobilized enzyme antibody method based on the principle of ELISA.
- ELISPOT Atssei secreted antibodies and cytokins are captured in situ by culturing immune cells on a plate on which antigens and antibodies are immobilized in advance, and quantification is performed based on the number of color spots formed by the secondary antibody and the substrate.
- ELISPOT has higher sensitivity than ELISA (about 20 to 200 times that of ELISA), is easy to operate, has excellent reproducibility, and has the advantage of being able to process multiple samples!
- Specific cytotoxic activity by activated CTL can be evaluated by the following method
- target cells stimulated with the test peptide for example, A24-positive cells or cancer cell lines
- peptide-specific T cells T cells induced by the test peptide
- the degree of peptide-specific cytotoxic activity can be calculated by subtracting the degree of cytotoxic activity against target cells not stimulated with the peptide from the level of cytotoxic activity against target cells stimulated with the peptide.
- the cytotoxic activity of T cells against each target cell can be quantitatively compared by comparing the radioactivity released from a certain number of target cells.
- ELISPOT Atssei can evaluate peptide-specific cytotoxic activity by quantifying granzyme B secreted from trace amounts of CTL with high sensitivity. [0028] 3. Evaluation of pharmacological activity
- transgenic mice expressing human HLA antigen can be produced, for example, by crossing a mouse in which the endogenous MHC region has been disrupted and a mouse in which the desired HLA coding region has been introduced by a known gene transfer method. .
- HLA-A24 transgenic mice can be produced based on the report of Gotoh et al. (Gotoh M, et al., Int J Cancer. 2002 Aug 10; 100 (5), p565_70).
- test peptide is emulsified with an appropriate adjuvant and administered to mice (for example, subcutaneous administration). Mice to which the test peptide has been administered are tested for cytotoxicity production and cytotoxicity according to the above-described method.
- immunogenicity of a test peptide can be tested by administering to a mouse a test peptide, an antigen derived therefrom, or a DNA vaccine for expressing them.
- the present inventors have identified a novel peptide useful as an HLA-A24-restricted tumor antigen peptide as a result of immunogenicity screening and a pharmacological effect test using HLA-A24 antigen-expressing transgenic mice. These peptides are shown in SEQ ID NOs: 4, 14, 15, 18, 19, 23, 24, 25, 27, 28, 29, 30, 34, 37, 38, 39, 40, 41, and 44 in the sequence listing. Having an amino acid sequence of
- the peptide may be appropriately modified depending on its use and within a range that does not impair the object of the present invention.
- the tumor antigen peptide when used for testing or diagnosis, may be labeled with an appropriate radioactive substance, fluorescent substance, protein, or the like, or may be immobilized on a plate or a capillary.
- the amino acids constituting the peptide are not limited to natural amino acids, and may be suitable derivatives.
- the tumor antigen peptide is used after adding an arbitrary amino acid sequence or a carrier (for example, keyhole limpet mosyanin).
- a carrier for example, keyhole limpet mosyanin
- the tumor antigen peptide of the present invention can be used as a peptide vaccine for HLA-A24 positive cancer patients (particularly liver cancer patients) by emulsifying with a suitable adjuvant.
- the adjuvant used is not particularly limited, including Freund's complete or incomplete adjuvant, bacteria and their cell components, mycobacterium, gram-negative bacteria and cell components, gram-positive bacteria and cell components, non-bacterial Adjuvants known in the art, such as substances, polysaccharides of plants and fungi, nucleic acids, fat-soluble vitamins, and mineral oils, can be used.
- the vaccine may also optionally include other pharmaceutically acceptable carriers.
- Antigen presentation on which the tumor antigen peptide of the present invention is presented can also be used as an anti-tumor vaccine for HLA-A24-positive cancer patients (particularly liver cancer patients). That is, the HLA-A24-positive antigen-presenting cells isolated from the patient are cultured together with the tumor antigen peptide of the present invention, and the tumor antigen peptide is incorporated into the antigen-presenting cells or directly binds to HLA-A24 on the cell surface. Let me show you. Then, the complex of the tumor antigen peptide and the antigen presenting cell (tumor antigen presenting cell) is returned to the living body of the same patient.
- the antigen-presenting cell used is not particularly limited as long as it is HLA-A24-positive, but is preferably a dendritic cell having strong antigen-presenting ability.
- the anti-tumor vaccine containing the antigen-presenting cells or tumor antigen peptide-presenting ⁇ cells that present the tumor antigen peptide of the present invention may contain an appropriate adjuvant or a pharmaceutically acceptable carrier, if necessary.
- the tumor antigen peptide of the present invention contains an epitope site, and thus an antibody against the peptide can be used as an antitumor agent for HLA-A24-positive cancer patients (particularly liver cancer patients) or for detection and diagnosis of tumors.
- the antibody of the present invention can be prepared by a conventional method (for example,
- a derivative obtained by adding an arbitrary amino acid sequence or a carrier to the tumor antigen peptide of the present invention can be used.
- a protein to be detected is bonded to a keyhole limpet as a carrier using a mosaicin.
- the obtained antibody is used for detection alone or in combination with a labeled secondary antibody that specifically recognizes the antibody as a primary antibody (recognizes an antibody derived from the animal from which the antibody was produced).
- a labeled secondary antibody that specifically recognizes the antibody as a primary antibody (recognizes an antibody derived from the animal from which the antibody was produced).
- labeled secondary antibody includes enzymes (alkaline phosphatase or horseradish peroxidase) or biotin or the like, but are not limited thereto.
- Various pre-labeled antibodies are commercially available as the labeled secondary antibody.
- the expression level of the protein to be detected can be measured by Western blotting, dot-Z slot blotting, or ELISA.
- the antibody is labeled with a radioisotope and measured with a liquid scintillation counter or the like.
- the present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of the tumor antigen peptide of the present invention.
- the nucleic acid molecule includes, for example, a nucleic acid (DNA, cDNA, RNA, cRNA) encoding the tumor antigen peptide of the present invention, and a vector containing the nucleic acid.
- An HLA-A24-positive cancer patient particularly a liver cancer patient
- the nucleic acid molecule of the present invention may be directly administered to an HLA-A24-positive cancer patient, or may be introduced into the isolated dendritic cells and returned to the patient.
- the nucleic acid molecule may be DNA or RNA, and may be single-stranded or double-stranded.
- the nucleic acid encoding the tumor antigen peptide of the present invention can be synthesized according to a method well known in the art.
- the vector for expressing the tumor antigen peptide of the present invention is prepared by appropriately ligating a promoter, a splice site, a polyadenylation site, a transcription termination sequence and the like upstream of the sequence to be expressed.
- the type of vector is not particularly limited, but safety and transformation efficiency Adenovirus vector or retrovirus vector is preferred. Methods for producing such vectors are already known in the art.
- the present invention provides a method for inducing cytotoxic T cells in vivo for CTL (TIL) therapy using the tumor antigen peptide of the present invention.
- TIL tumor-infiltrating lymphocytes
- TILs tumor-infiltrating lymphocytes
- PBMC peripheral blood lymphocytes
- CTLs having cytotoxic activity are induced by culturing TIL or PBMC from which the ability of HLA-A24-positive cancer patients has been collected in the presence of the tumor antigen peptide of the present invention and IL-2.
- the induced CTL is cultured and proliferated as appropriate, and administered to the patient. In this case, it may be administered together with a pharmaceutically acceptable carrier!
- the tumor antigen peptide of the present invention is an epitope of an antigen specifically expressed on tumor cells. Including. Therefore, the tumor antigen peptide of the present invention, ie, an antibody against the peptide, can be used for screening antitumor agents and detecting cancers. For example, by comparing the expression level of the tumor antigen peptide of the present invention before and after administration of the test substance, the effect of the test substance as an antitumor agent can be evaluated. For measurement of the expression level of the tumor antigen peptide, the above-described antibody of the present invention can be used. In addition, cancer can be diagnosed using the expression level of the tumor antigen peptide in the sample as an index.
- telomerase reverse transcriptase Ten peptides derived from telomerase reverse transcriptase (hTERT) were produced (Table 2).
- MRP3 NYSVRYRPGL HLA-A24 As control for each assay, it is derived from human immunodeficiency virus (HIV), Epstain-Barr virus (EBV), and cytomegalovirus (CMV). The peptide was reported to have high compatibility, and was prepared (Table 4).
- tumor markers alpha-fetoprotein; AFP
- PBMC peripheral blood mononuclear cells
- a lymphocyte separation tube After collecting 50 ml of patient's venous blood into a heparin blood collection tube (TERUMO, Tokyo, Japan) and diluting it twice with PBS (GibcoBRL, Tokyo, Japan), a lymphocyte separation tube
- a 96-well plate (MILLIPORE, Tokyo, Japan) was coated with an anti-human interferon-gamma antibody (MABTECH, Nacka, Sweden) at 4 ° C for 12 hours. After aseptically washing four times with 200 1 of PBS per well, blocking was performed at 25 ° C for 1 hour using 10% FCS RPMI medium. Extract the PBMC that are cryopreserved, washed twice with PBS, and resuspended in 10% FCS RPMI medium, 30 hours 3Xl0 5 pieces of per 1 well with peptide (final concentration 10 g / ml), at 37 ° C for Cultured.
- the plate was washed four times with PBS and four times with l% Tween-PBS, and incubated at 4 ° C for 12 hours using an anti-human interferon-gamma antibody labeled with biotin (MABTECH, Nacka, Sweden). Thereafter, the plate was washed four times with l% Tween-PBS, and streptoavidin-AP (MABTECH, Nacka, Sweden) was added and incubated for 2 hours. After washing the plate 4 times with PBS, NBT / BCIP (nitroblue
- the number of spots specific to the peptide was calculated by subtracting the number of spots of the well to which no peptide was added from the number of spots of the well to which the peptide was added.
- PBMCs were cultured in wells containing PMA (SIGMA-ALDRICH, Tokyo, Japan) and Ionomycin (SIGMA-ALDRICH, Tokyo, Japan) as Atsushi controls, and those with 50 or more spots were counted as data.
- PMA SIGMA-ALDRICH, Tokyo, Japan
- Ionomycin SIGMA-ALDRICH, Tokyo, Japan
- the number of specific spots for each peptide of 11 healthy adults was measured, and the average + 2SD was less than 10 spots in each case. Those showing more than twice the number of spots in this case were judged as positive.
- 96 well round bottom plates were used (BD, NJ, USA) lxlO 5 amino T2-A24 cells per 1 well. After culturing at 25 ° C for 10 hours using 10% FCS RPMI medium, the peptide was administered to each concentration, and the cells were further cultured for 2 hours. Culture was continued at 37 ° C for 2 hours to degrade HLA-A24 molecules not bound to the peptide. After completion of the culture, the mixture was centrifuged at 1700 rpm for 5 minutes, and the supernatant was discarded.
- HLA-A24 molecule was prepared as a negative control.
- the expression level of the HLA-A24 molecule was displayed using% mean FI increase or mean FI, and the values of the control peptide and the target peptide were compared and examined.
- C1RA24 cells stimulated with 10 ⁇ g / ml peptide for 12 hours
- HLA-A24 positive C1R cells AIDS Research Center, Kumamoto University ⁇ Provided by Professor Masafumi Takiguchi in the field of virus control
- the cells were labeled with Cr (Amersham-Phamacia, Tokyo, Japan) for 1 hour, washed with PBS, mixed with peptide-specific T cells at various cell ratios, and subjected to a 4-hour cytotoxicity test.
- HepG2 cells, Huh7 cells, HLE cells, and K562 cells were similarly labeled with 51 Cr of Ci and used as target cells.
- the degree of the peptide-specific cytotoxic activity was calculated by subtracting the degree of the cytotoxic activity against the target cells stimulated with the peptide from the intensity of the cytotoxic activity against the target cells stimulated with the peptide.
- the mouse cytotoxicity test Jurkat-A2402 / Kb cells obtained by introducing HLA-A24 / Kb cDNA into Jurkat cells derived from human leukemia cells were used as target cells.
- HepG2 cells, Huh7 cells, and HLE cells were cultured using 10% FCS D-MEM medium (GibcoBRL, Tokyo, Japan).
- K562 cells were cultured using 10% FCS RPMI medium.
- C1RA24 cells were cultured using 10% FCS RPMI medium containing 0.5 mg / ml Hyglomycin (SIGMA-ALDRICH, Tokyo, Japan). 800 g / ml G418 for T2-A24 cells
- FCS IMDM medium obtained by caulking.
- Jurkat-A2402 / Kb cells were cultured using 10% FCS RPMI medium containing 0.5 mg / ml G418. Each medium was supplemented with 100 U / ml penicillin and 100 g / ml streptomycin, and cultured at 37 ° C under 5% CO.
- Induction of peptide-specific T cells from human PBMC by peptide was performed using a 96-well round bottom plate. Using 4 x 10 PBMCs per well, 10 g / ml peptide, rIL-7 (10 ng / ml) (SIGMA-ALDRICH, Tokyo, Japan), rIL-12 (100 pg / ml)
- mice Safety and immunity of peptide vaccine using HLA-A24 / Kb transgenic mice (Sumitomo Pharmaceutical, Tokyo, Japan: Gotoh M, et al "Int J Cancer. 2002 Aug 10; 100 (5), p565-70)
- Male mice aged 6-8 weeks were used for the experiments, and 200 ⁇ g of peptide emulsified with IFA (Wako, Osaka, Japan) and 100 ⁇ g of tetanus toxoid were subcutaneously injected into the mice.
- IFA Wired, Osaka, Japan
- tetanus toxoid 100 ⁇ g of tetanus toxoid were subcutaneously injected into the mice.
- the spleen was excised, spleen cells were extracted using 10% FBS RPMI medium, and spleen cells were extracted.
- a vector (MGC-34639, ATCC, VA, USA) that expresses human AFP protein under the CMV promoter into E. coli, amplified it, and amplified it using QIAGEN (Hilden , Germany) and dissolved in saline at a concentration of 1 ⁇ g / ml.
- Fig. 4 shows the results of an experiment of binding of an AFP-derived peptide to HLA-A24 molecule.
- Peptide Nos. 27, 28, 29, 30, 31, 32, and 34 showed relatively strong binding affinities.
- the positive control 49 showed strong binding and the negative control No. 50 showed no binding.
- FIG. 3 and FIG. 4 show the results of IFN- ⁇ ELISPOT ATSSE using PBMCs derived from healthy persons and liver cancer patients, respectively.
- PBMCs derived from healthy individuals no positive response was observed for the AFP-derived peptide, but in PBMCs derived from liver cancer patients, Peptide No. 27, 28, 29, 30, 31 out of 10 peptides , 32,34 showed positive responses.
- Peptide Nos. 27, 29 and 30 the responses were higher than those of EBV (No. 47) and CMV (No. 48), which showed a high frequency of response.
- the response to EBV and CMV-derived peptides did not differ in the positive frequency between healthy subjects and liver cancer patients, and the response to HIV-derived peptides was not recognized in healthy subjects and liver cancer patients.
- lymphocytes that react with the AFP-derived peptide is specific to liver cancer patients, and that these peptides may contain the AFP-derived HLA-A24-restricted CTL epitope.
- Lymphocytes from liver cancer patients were stimulated using 10 types of AFP-derived peptides to try to induce AFP-specific CTL.
- Peptide Nos. 27, 28, 29, 30, and 34 were able to induce AFP-specific CTL (Fig. 5).
- Peptide No. 30 showed strong immunogenicity in healthy individuals
- Peptide Nos. 27 and 30 are specific to HepG2 cell line only While exhibiting cytotoxic activity, it expressed HLA-A24 and AFP, but did not exhibit cytotoxic activity against other cell lines. Therefore, it was confirmed that the cytotoxic activity of Peptide Nos. 27 and 30 was HLA-A24-restricted and AFP-specific.
- AFP-derived from the AFP identified this time, changes in the immune response before and after treatment of liver cancer patients were examined using ELISPOT ATSEY (Fig. 7-2). After treatment, the number of AFP-specific CTLs in peripheral blood increased in seven patients. On the other hand, HIV-derived epitope-specific CTLs did not change before and after treatment. CMV-derived epitope-specific CTLs increased only in one person. This indicates that the change of AFP-specific CTL is specific for liver cancer treatment. The epitope identified this time was considered to be useful for analyzing the immune response of such cancer patients before and after treatment.
- FIG. 8 shows the results of the T cell response (IFN- ⁇ ELISPOT ATSE) of HLA-A24 transgenic mice inoculated with Peptide Nos. 27 and 30.
- Mice immunized with Peptide No. 27 or 30 showed significant CTL induction compared to mice immunized with the negative control Peptide No. 47. No adverse reactions were observed in all mice against immunization with peptides, confirming the safety of these peptides.
- FIG. 9 shows the results of an immunogenicity test by DNA vaccine administration.
- Peptide For No. 30, strong immunogenicity was confirmed.
- FIG. 10 shows the results of CTL assays using spleen cells of mice immunized with Peptide No. 30 or its DNA vaccine. As is clear from FIG. 10, it was confirmed that even when the peptide vaccine and the DNA vaccine were used, CTLs specific to Peptide No. 30 could be induced.
- FIGS. 11 and 12 show the results of IFN- ⁇ ELISPOT assays using PBMCs derived from healthy persons and liver cancer patients, respectively. No positive response was observed for any tumor-associated antigen-derived peptide in PBMCs derived from healthy individuals, but in PBMCs derived from liver cancer patients, the frequency of T cells responding to peptides derived from various antigens in parentheses () was recognized. Positive responses were observed at particularly high frequency for the three peptides, Peptide No. 14 derived from SART2, Peptide No. 15 derived from SART3, and Peptide No. 23 derived from MRP3.
- cytotoxic activity was evaluated for each peptide. As a result, cytotoxic activities were confirmed for some peptides including Peptide Nos. 14, 15, and 23 (FIG. 13).
- ELISPOT and CTL assays were performed using peripheral blood lymphocytes from 72 liver cancer patients (see next section).
- a study was performed using lymphocytes from 11 healthy subjects as a control.
- the clinical background of the subjects is shown in Table 7 below.
- Diagnosis Patients Mean-SD Mean SD (ng / ml) (B / COthers) (A / B / C) (Large ⁇ mall) (Multiple / Solitary) Invasion ⁇ /-) (Wel / od / Por.'ND) ( (Lll / III ⁇ HIb / IIIc / IV)
- lymphocytes producing IFN- ⁇ were detected for Peptide Nos. 37, 38, 39, 40, 41, and 44 (Fig. 16).
- lymphocytes that responded to these peptides were not detected in healthy subjects.
- No lymphocytes were detected in response to the HIV-derived peptide, and the frequency of positivity for the CMV-derived peptide was comparable.
- the above results suggest that lymphocytes that react with the hTERT-derived peptide are specifically present in the peripheral blood of liver cancer patients, suggesting that this peptide contains the A24-restricted epitope of hTERT! / .
- CTLs thus induced exhibited cytotoxic activity against cancer cells was examined using a cultured liver cancer cell line (Fig. 18).
- CTLs induced by Peptide Nos. 39 and 40 showed strong cytotoxic activity against HepG2 cells, which are cancer cells expressing HLA-A24 and hTERT.
- strong expression of cytotoxic activity against K562 cells without HLA expression was demonstrated.
- FIG. 20 shows the results of the T cell response (IFN- ⁇ ELISPOT ATSEY) of the HLA-A24 transgenic mouse.
- IFN- ⁇ ELISPOT ATSEY T cell response
- the tumor antigen peptide of the present invention DNA encoding the peptide can be used for peptide vaccine, DC vaccine, DNA vaccine, and CTL therapy for HLA-A24-positive cancer patients (particularly liver cancer patients). Further, the tumor antigen peptide of the present invention—an antibody against the peptide can be used for screening antitumor agents and diagnosing cancer.
- SEQ ID NO: 1 Description of artificial sequence: ART1-derived synthetic peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006510525A JPWO2005083074A1 (ja) | 2004-03-01 | 2005-03-01 | 腫瘍抗原ペプチド |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004056865 | 2004-03-01 | ||
JP2004-056865 | 2004-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005083074A1 true WO2005083074A1 (ja) | 2005-09-09 |
Family
ID=34908997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/003399 WO2005083074A1 (ja) | 2004-03-01 | 2005-03-01 | 腫瘍抗原ペプチド |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005083074A1 (ja) |
WO (1) | WO2005083074A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010005069A1 (ja) * | 2008-07-10 | 2010-01-14 | 東レ株式会社 | 免疫誘導剤及び癌の検出方法 |
EP2591799A4 (en) * | 2010-07-07 | 2014-06-11 | Greenpeptide Co Ltd | CANCER PEPTIDE VACCINE |
US9102715B2 (en) | 2007-09-18 | 2015-08-11 | Green Peptide Co., Ltd. | CTL inducer composition |
JP2017081836A (ja) * | 2015-10-23 | 2017-05-18 | 国立大学法人金沢大学 | 細胞傷害性t細胞の作製方法 |
WO2018164637A1 (en) * | 2017-03-08 | 2018-09-13 | Agency For Science, Technology And Research | T cell receptor like antibodies that bind to p53-mhc class i complex |
US10611835B2 (en) | 2008-07-10 | 2020-04-07 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
JP2020195379A (ja) * | 2015-10-23 | 2020-12-10 | 国立大学法人金沢大学 | 細胞傷害性t細胞の作製方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020306A1 (fr) * | 2001-08-29 | 2003-03-13 | Kyogo Itoh | Desensibilisants |
-
2005
- 2005-03-01 JP JP2006510525A patent/JPWO2005083074A1/ja active Pending
- 2005-03-01 WO PCT/JP2005/003399 patent/WO2005083074A1/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020306A1 (fr) * | 2001-08-29 | 2003-03-13 | Kyogo Itoh | Desensibilisants |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9102715B2 (en) | 2007-09-18 | 2015-08-11 | Green Peptide Co., Ltd. | CTL inducer composition |
US9642900B2 (en) | 2007-09-18 | 2017-05-09 | Green Peptide Co., Ltd. | CTL inducer composition |
WO2010005069A1 (ja) * | 2008-07-10 | 2010-01-14 | 東レ株式会社 | 免疫誘導剤及び癌の検出方法 |
US8901082B2 (en) | 2008-07-10 | 2014-12-02 | Toray Industries, Inc. | Immunity-inducing agent and method for detection of cancer |
JP5703562B2 (ja) * | 2008-07-10 | 2015-04-22 | 東レ株式会社 | 免疫誘導剤及び癌の検出方法 |
US10611835B2 (en) | 2008-07-10 | 2020-04-07 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
US11993650B2 (en) | 2008-07-10 | 2024-05-28 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
EP2591799A4 (en) * | 2010-07-07 | 2014-06-11 | Greenpeptide Co Ltd | CANCER PEPTIDE VACCINE |
JP2017081836A (ja) * | 2015-10-23 | 2017-05-18 | 国立大学法人金沢大学 | 細胞傷害性t細胞の作製方法 |
JP2020195379A (ja) * | 2015-10-23 | 2020-12-10 | 国立大学法人金沢大学 | 細胞傷害性t細胞の作製方法 |
WO2018164637A1 (en) * | 2017-03-08 | 2018-09-13 | Agency For Science, Technology And Research | T cell receptor like antibodies that bind to p53-mhc class i complex |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005083074A1 (ja) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hörig et al. | Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7. 1 co-stimulatory molecule | |
Komori et al. | Identification of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma | |
Sawada et al. | Phase I trial of a glypican-3–derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival | |
Tsuda et al. | Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers | |
Okuno et al. | Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer | |
Cormier et al. | Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A | |
Butterfield et al. | T-cell responses to HLA-A* 0201 immunodominant peptides derived from α-fetoprotein in patients with hepatocellular cancer | |
Scheibenbogen et al. | Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ‐ELISPOT assay | |
Mizukoshi et al. | Comparative analysis of various tumor‐associated antigen‐specific t‐cell responses in patients with hepatocellular carcinoma | |
de Vos van Steenwijk et al. | An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer | |
AU2004208469B2 (en) | Survivin-derived peptides and use thereof | |
Honma et al. | Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer | |
Uemura et al. | A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma | |
Perez et al. | Results from a phase I clinical study of the novel Ii-Key/HER-2/neu (776–790) hybrid peptide vaccine in patients with prostate cancer | |
Mizukoshi et al. | Identification of α‐fetoprotein‐derived peptides recognized by cytotoxic T lymphocytes in HLA‐A24+ patients with hepatocellular carcinoma | |
WO2005083074A1 (ja) | 腫瘍抗原ペプチド | |
Machlenkin et al. | Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy | |
RU2009122204A (ru) | Микроорганизмы и их фракции, индуцирующие специфичный к углеводу клеточный иммунитет | |
Kawashima et al. | Identification of GP100‐derived, melanoma‐specific cytotoxic T‐lymphocyte epitopes restricted by HLA‐A3 supertype molecules by primary in vitro immunization with peptide‐pulsed dendritic cells | |
Zhang et al. | Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro | |
Han et al. | Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy | |
Pullarkat et al. | A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma | |
WO2003050140A1 (fr) | Antigenes tumoraux | |
Matsui et al. | Identification of a promiscuous epitope peptide derived from HSP70 | |
Brinck-Jensen et al. | Immunogenicity of twenty peptides representing epitopes of the hepatitis B core and surface antigens by IFN-γ response in chronic and resolved HBV |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510525 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |